Vitiligo
☆ AI Dermatology — Free Service
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Vitiligo sou men yo pi difisil pou trete pase lòt zòn. Anplis de sa ki koz pwoblèm kozmetik, Vitiligo se yon kondisyon ki nòmal epi li pa kontajye. Nan dèrmatoloji, tretman ki pi efikas se fototerapi oswa tretman lazè (excimer) 2‑3 fwa pa semèn pou omwen yon ane. Si ou pa ka ale lopital la souvan pou rezon finansye oswa paske ou okipe, ou ka eseye yon aparèy fototerapi ki apwouve pou itilizasyon lakay ou.
Vitiligo po ak je.
Vitiligo sou men
relevance score : -100.0%
ReferencesVitiligo se yon maladi po komen ki lakòz plak blan sou po a akòz pèt melanosit yo. Dènye rechèch yo montre li se yon maladi otoiminitè. Pandan ke souvan li konsidere kòm yon pwoblèm kosmetik, li ka afekte pwofondman byennèt mantal ak lavi chak jou. An 2011, ekspè yo te klase yon kalite ki rele segmental vitiligo separeman de lòt kalite.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Pasyan ki gen vitiligo aktif yo gen plizyè opsyon terapi, tankou glikokortikoyid sistemik, fototerapi, ak imunosupresif sistemik. Pasyan ki gen vitiligo ki estab ka jwenn soulajman ak kortikoterapi topikal, inibitè calcineurin topikal, fototerapi, ak pwosedi transplantasyon po. Avansman ki sot pase yo nan konpreyansyon pwosesis ki kache dèyè vitiligo a te mennen nan devlopman terapi vize. Kounye a, inibitè JAK yo se pi pwomèt yo, ki ofri bon tolerabilite ak rezilta fonksyonèl, malgre risk pou aktive enfeksyon ki inaktif ak efè segondè sistemik ki komen ak lòt ajan imunosupresif. Rechèch kontinyèl gen pou objaktif pou idantifye sitokin kle ki enplike nan devlopman vitiligo a (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Bloke cytokines sa yo te montre pwomès nan modèl bèt ak kèk pasyan. Anplis de sa, envestigasyon sou terapi ki baze sou miRNA ak terapi adoptif selil Treg ap fèt.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Pa gen okenn gerizon ki konnen pou vitiligo. Pou moun ki gen po limyè, krèm pwotèj kont solèy ak makiyaj se tout sa ki tipikman rekòmande. Lòt opsyon tretman ka gen ladan krèm esteroid oswa fototerapi.
○ Tretman
#Phototherapy
#Excimer laser
#Tacrolimus ointment